Inflammatory indices, such as the neutrophil-to-lymphocyte (NLR) and lymphocyte-to-monocyte (LMR) ratios, may help determine the efficacy of atezolizumab monotherapy in patients with nonsmall cell lung cancer (NSCLC), a recent study has found.
Advanced stages of chronic obstructive pulmonary disease (COPD) are associated with significantly lower body mass index (BMI), fat-free body mass, hand grip strength, and respiratory and skeletal muscle functions, reports a recent study.
Body mass index (BMI) and lung function are lower in patients with pleuroparenchymal fibroelastosis (PPFE) compared with those without, according to a study. The PPFE arm also has more frequent complications and poorer survival during follow-up.
Two months of average volume‐assured pressure support—automated expiratory positive airway pressure (AVAPS‐AE) is comparable to pressure support (ST) ventilation in terms of effect on sleep quality and gas exchange among patients with obesity hypoventilation syndrome (OHS), a recent study has shown.
While gastroesophageal reflux disease is a common comorbidity in idiopathic pulmonary fibrosis (IPF), treatment with a proton pump inhibitor does not appear to have any bearing on mortality and hospitalization outcomes among IPF patients, according to real-world data.
A recent study has shown notable characteristics of patients with chronic obstructive pulmonary disease (COPD) in advanced stages, which include decreased body mass index (BMI), fat-free body mass, hand grip strength, and respiratory and skeletal muscle functions.
Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.
Regular, low-dose, oral sustained-release morphine improved the health status of patients with moderate-to-very-severe chronic breathlessness due to chronic obstructive pulmonary disease (COPD), the MORDYC* trial has shown, validating its palliative role for chronic breathlessness.